Amanda K. Murphy

Partner
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

​​

Amanda Murphy, Ph.D., brings over 17 years of experience to her life sciences intellectual property practice. As a U.S. patent attorney practicing in London, Amanda is ideally situated to counsel clients on their global patent strategies. Her practice includes patent application preparation and prosecution, pre-litigation portfolio and due diligence analyses, and contentious PTAB proceedings.
 Amanda focuses on developing patent filing and prosecution strategies tailored to clients’ worldwide business goals. She works with a wide range of clients, including small biotech startup companies, research foundations, and large publicly traded biotechnology and pharmaceutical companies.
 Amanda prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants in ex parte appeals before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has also led clients through numerous reissue applications, inter partes and ex parte reexamination applications, and supplemental examination proceedings.
 Amanda’s extensive client counseling practice includes providing patentability, freedom-to-operate, infringement, and validity opinions. In addition, she represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB.

Amanda has substantial experience in a wide variety of life sciences technologies, including antibodies and antibody drug conjugates; antiretrovirals and anticancer agents; biologics; blood clotting factors; cell signaling and signal transduction; diagnostic markers and detection assays; drug formulations; gene delivery systems, including AAV; gene editing technologies, including CRISPR; immunooncology; lipid nanoparticles; microbiome analysis and probiotics; nucleic acid modifications; peptide synthesis and protein purification; single-cell and single-molecule analysis; small molecule drugs; and vaccines.
 Prior to joining Finnegan, Amanda received her Ph.D. from Cornell University, where she studied the molecular requirements for protein-lipid interactions during retroviral assembly and the lipid compositions of retroviral particles. She then gained significant experience as a technical specialist and a student associate at Finnegan during her studies in law school.
 Amanda was recognized as a Best Mentor by Corporate Counsel’s Women, Influence and Power in Law.
 Et Cetera
Serves as an adjunct professor teaching a patent prosecution practice class at Georgetown University Law Center, 2013-present.

Speech title & Synopsis

Navigating your Life Sciences Post-Grant Challenges:  Tips for best practice when you are challenging or being challenged in the EPO or USPTO
 
The Biologics Price Competition and Innovation Act (BPCIA) and the Changing Landscape for Biologics and Biosimilars
 
Panel Discussion:  The Impact of Clinical Trials on Patentability—novelty, non-obviousness, and inherency

Obtaining global protection for your innovation can be challenging, particularly when considering the different rules and legal systems in the USA and Europe.  In this seminar we will explain the post-grant challenges to patents that can be launched in the USA and in Europe, highlighting the opportunities and potential pitfalls within the two legal systems.  We will also discuss the Biologics Price Competition and Innovation Act (BPCIA) in the USA and the litigation that has followed.  Finally, we will have a panel discussion on the impact of clinical trials on patentability of inventions, addressing the relevance of publication of clinical trial data to assessment of novelty and inventive step in both the USA and in Europe.